Editorial: Mitochondrial plasticity and quality control in health and diseaseFrancesca Forini, Milena Rizzo, Elena Levantini et al.|Frontiers in Cell and Developmental Biology|2024Cited by 2
Reprogramming of Osimertinib-Resistant EGFR-mutant NSCLC: The Pyruvate-Acetaldehyde-Acetate Pathway As a Key Driver of ResistanceGiorgia Maroni, Elena Levantini, Eva Cabrera San Millán et al.|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 1
Dual actionability of BMI1 activation and mitotic vulnerability defines adaptive Osimertinib resistance in EGFR-mutant NSCLCPaolo Armanetti, Giorgia Maroni, Stefania Crucitta et al.|Cell Death and Disease|2026Cited by 1
The two sides of resistance: aggressiveness and mitotic instability as the Achilles’ heel of Osimertinib-resistant NSCLCPaolo Armanetti, Giorgia Maroni, Eva Cabrera San Millán et al.|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 0
P3.03.15 Investigating Mechanisms of Resistance in EGFR-Mutated Non-Small Cell Lung Cancer Through High Resolution TranscriptomicsEva Cabrera San Millán, Elena Levantini, Luca Celli et al.|Journal of Thoracic Oncology|2025Cited by 0